Latest & greatest articles for tuberculosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tuberculosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tuberculosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tuberculosis

641. Preventive therapy for tuberculosis in HIV-infected persons: analysis of policy options based on tuberculin status and CD4+ cell count

Preventive therapy for tuberculosis in HIV-infected persons: analysis of policy options based on tuberculin status and CD4+ cell count Preventive therapy for tuberculosis in HIV-infected persons: analysis of policy options based on tuberculin status and CD4+ cell count Preventive therapy for tuberculosis in HIV-infected persons: analysis of policy options based on tuberculin status and CD4+ cell count Sawert H, Girardi E, Antonucci G, Raviglione M C, Viale P, Ippolito G Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Preventive therapy for tuberculosis in HIV-infected persons. The following five intervention strategies were considered: Isoniazid preventive therapy (IPT) for tuberculin-positive cohort members only; IPT

1998 NHS Economic Evaluation Database.

642. An effectiveness and cost analysis of presumptive treatment for Mycobacterium tuberculosis

An effectiveness and cost analysis of presumptive treatment for Mycobacterium tuberculosis An effectiveness and cost analysis of presumptive treatment for Mycobacterium tuberculosis An effectiveness and cost analysis of presumptive treatment for Mycobacterium tuberculosis Brewer T F, Heymann S J, Ettling M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Presumptive treatment of mycobacterium tuberculosis (TB). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population HIV-negative or status unknown patients being evaluated for TB. Setting Hospital. The study was carried out in the USA. Dates to which data relate Effectiveness data were collected from studies published between 1974

1998 NHS Economic Evaluation Database.

643. Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis

Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis Gourevitch M N, Alcabes P, Wasserman W C, Arno P S Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Direct observation of patients in order to improve compliance with therapy. In this case the example used chemoprophylaxis, specifically isoniazid (INH) for the prevention of tuberculosis, a regimen whose effectiveness depends heavily on patient compliance. Type

1998 NHS Economic Evaluation Database.

644. Cost-effectiveness analysis of tuberculosis control policies in Ivanovo Oblast, Russia

Cost-effectiveness analysis of tuberculosis control policies in Ivanovo Oblast, Russia Cost-effectiveness analysis of tuberculosis control policies in Ivanovo Oblast, Russia Cost-effectiveness analysis of tuberculosis control policies in Ivanovo Oblast, Russia Migliori G B, Khomenko A G, Punga V V, Ambrosetti M, Danilova I, Ribka L N, Grzemska M, Sawert H, Raviglione M C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology WHO tuberculosis control policy: case-finding among symptomatic patients self-reporting to health services and shorter regimens implemented in Ivanovo Oblast, Russian Federation. The following three scenarios were considered: 10% of patients were admitted for the intensive phase and WHO recommended regimens

1998 NHS Economic Evaluation Database.

645. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. (PubMed)

Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Tuberculosis is a common complication of HIV-1 infection, especially in developing countries. Practical and effective chemoprophylaxis regimens for HIV-1-related tuberculosis are needed. Our aim was to test the efficacy of isoniazid versus rifampicin with pyrazinamide for prevention of tuberculosis in HIV-1-positive individuals.We compared the efficacy of 6 months of isoniazid (...) with 2 months of rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1-seropositive individuals. Eligible participants were aged 16-77 years, HIV-1 seropositive, had a positive purified-protein derivative (PPD) skin test reaction of at least 5 mm, and had a normal chest radiograph. Participants were randomly assigned partially supervised twice weekly isoniazid for 24 weeks or twice weekly rifampicin and pyrazinamide for 8 weeks. Participants were followed up for up to 4 years

1998 Lancet Controlled trial quality: predicted high

646. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. (PubMed)

Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Tuberculosis is a major public-health problem in South Africa, made worse by poor adherence to and frequent interruption of treatment. Direct observation (DO) of tuberculosis patients taking their drugs is supposed to improve treatment completion and outcome. We compared DO with self-supervision, in which patients on the same drug regimen are not observed taking their pills, to assess the effect (...) of each on the success of tuberculosis treatment.We undertook an unblinded randomised controlled trial in two communities with large tuberculosis caseloads. The trial included 216 adults who started pulmonary tuberculosis treatment for the first time, or who had a second course of treatment (retreatment patients). No changes to existing treatment delivery were made other than randomisation. Analysis was by intention to treat. Individual patient data from the two communities were combined.Treatment

1998 Lancet Controlled trial quality: uncertain

647. Systematic review of randomised controlled trials of strategies to promote adherence to tuberculosis treatment. (PubMed)

Systematic review of randomised controlled trials of strategies to promote adherence to tuberculosis treatment. To determine the effectiveness of strategies to promote adherence to treatment for tuberculosis.Searches in Medline (1966 to August 1996), the Cochrane trials register (up to October 1996), and LILACS (Literatura Latinoamericana y del Caribe en Ciencias de la Salud) (1982 to September 1996); screening of references in articles on compliance and adherence; contact with experts (...) in research on tuberculosis and adherence.Randomised or pseudorandomised controlled trials of interventions to promote adherence with curative or preventive treatment for tuberculosis, with at least one measure of adherence.Relative risks and 95% confidence intervals for estimates of effect for categorical outcomes.Five trials met the inclusion criteria. The relative risk for tested reminder cards sent to patients who defaulted on treatment was 1.2 (95% confidence interval 1.1 to 1.4), for help given

Full Text available with Trip Pro

1997 BMJ

648. Effectiveness and cost of rapid and conventional laboratory methods for Mycobacterium tuberculosis screening

Effectiveness and cost of rapid and conventional laboratory methods for Mycobacterium tuberculosis screening Effectiveness and cost of rapid and conventional laboratory methods for Mycobacterium tuberculosis screening Effectiveness and cost of rapid and conventional laboratory methods for Mycobacterium tuberculosis screening Heymann S J, Brewer T F, Ettling M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Rapid methods for diagnosis of tuberculosis (high-performance liquid chromatography, nucleic acid probes and paranitro-alpha-acetylamino-beta-hydroxy-propriophenone) and testing for drug susceptibility (radiometric broth). Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis. Study

1997 NHS Economic Evaluation Database.

649. The cost-effectiveness of preventing tuberculosis in physicians using tuberculin skin testing or a hypothetical vaccine

The cost-effectiveness of preventing tuberculosis in physicians using tuberculin skin testing or a hypothetical vaccine The cost-effectiveness of preventing tuberculosis in physicians using tuberculin skin testing or a hypothetical vaccine The cost-effectiveness of preventing tuberculosis in physicians using tuberculin skin testing or a hypothetical vaccine Nettleman M D, Geerdes H, Roy M C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Tuberculin skin testing using the purified protein derivative combined with a 6-month prophylactic isoniazid regimen in preventing pulmonary tuberculosis in physicians. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population A population

1997 NHS Economic Evaluation Database.

650. Screening pulmonary tuberculosis suspects in Malawi: testing different strategies

Screening pulmonary tuberculosis suspects in Malawi: testing different strategies Screening pulmonary tuberculosis suspects in Malawi: testing different strategies Screening pulmonary tuberculosis suspects in Malawi: testing different strategies Harries A D, Kamenya A, Subramanyam V R, Maher D, Squire S B, Wirima J J, Nyangulu D S, Nunn P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Screening pulmonary tuberculosis (PTB) suspects using two hypothetical strategies: (1) screen by sputum smear then chest X-ray (CXR) on smear negative patients, or (2) screen by chest radiograph then sputum smear on patients with CXR consistent with tuberculosis (TB). Type of intervention Screening. Economic study type Cost-effectiveness analysis

1997 NHS Economic Evaluation Database.

651. Comparison of induced versus expectorated sputum for diagnosis of pulmonary tuberculosis by acid-fast smear

Comparison of induced versus expectorated sputum for diagnosis of pulmonary tuberculosis by acid-fast smear Comparison of induced versus expectorated sputum for diagnosis of pulmonary tuberculosis by acid-fast smear Comparison of induced versus expectorated sputum for diagnosis of pulmonary tuberculosis by acid-fast smear Merrick S T, Sepkowitz K A, Walsh J, Damson L, McKinley P, Jacobs J L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Induced versus expectorated sputum for diagnosis of pulmonary tuberculosis by acid-fast smear. Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis. Study population Male and female patients with cultures from respiratory secretions that were positive

1997 NHS Economic Evaluation Database.

652. Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia

Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia Foster S, Godfrey-Faussett P, Porter J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Using daily isoniazid (300 mg, four-times daily) for tuberculosis (TB) preventive therapy programme (TB PTP) in HIV-infected subjects. Depending on the site and the time horizon of the study, six scenarios were considered: (1) the preventive program is implemented in a voluntary testing and counselling site

1997 NHS Economic Evaluation Database.

653. A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis

A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis Burman W J, Dalton C B, Cohn D L, Butler J R G, Reves R R Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Directly observed therapy in the treatment of active tuberculosis. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients with initial drug-susceptible tuberculosis. Setting Hospital. The study was carried out

1997 NHS Economic Evaluation Database.

654. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. (PubMed)

A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. Infection with the human immunodeficiency virus (HIV) greatly increases the risk of reactivation tuberculosis. We evaluated the safety and efficacy of three preventive-therapy regimens in a setting where exposure to tuberculosis is common.We performed a randomized, placebo-controlled trial in 2736 HIV-infected adults (...) subjects) or six months of isoniazid (395). The medications were dispensed monthly and were self-administered.Among the PPD-positive subjects, the incidence of tuberculosis in the three groups that received preventive therapy was lower than the rate in the placebo group (P=0.002 by the log-rank test). The relative risk of tuberculosis with isoniazid alone, as compared with placebo, was 0.33 (95 percent confidence interval, 0.14 to 0.77); with isoniazid and rifampin, 0.40 (0.18 to 0.86

1997 NEJM Controlled trial quality: predicted high

655. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. (PubMed)

A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. Patients with human immunodeficiency virus (HIV) infection and latent tuberculosis are at substantial risk for the development of active tuberculosis. As a public health measure, prophylactic treatment with isoniazid has been suggested for HIV-infected persons who have anergy and are in groups (...) with a high prevalence of tuberculosis.We conducted a multicenter, randomized, double-blind, placebo-controlled trial of six months of prophylactic isoniazid treatment in HIV-infected patients with anergy who have risk factors for tuberculosis infection. The primary end point was culture-confirmed tuberculosis.The study was conducted from November 1991 through June 1996. Over 90 percent of the patients had two or more risk factors for tuberculosis infection, and nearly 75 percent of patients were from

Full Text available with Trip Pro

1997 NEJM Controlled trial quality: predicted high

656. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis

Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis Moore R D, Chaulk C P, Griffiths R, Cavalcante S, Chaisson R E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) in the synthesis section appears to lend support to the final results. Source of funding Supported in part by Marion Merrell Dow, Inc. Bibliographic details Moore R D, Chaulk C P, Griffiths R, Cavalcante S, Chaisson R E. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. American Journal of Respiratory and Critical Care Medicine 1996; 154(4): 1013-1019 PubMedID DOI Indexing Status Subject indexing assigned by NLM MeSH Antitubercular Agents /administration & Cost-Benefit

1996 NHS Economic Evaluation Database.

657. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group. (PubMed)

Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group. Repeat BCG vaccination is standard practice in many countries for prevention of tuberculosis and leprosy, but its effectiveness has not been evaluated. The addition of Mycobacterium leprae antigens to BCG might improve its effectiveness against leprosy. A double-blind, randomised, controlled trial (...) plus killed M leprae (8102). Incident cases of leprosy and tuberculosis were ascertained over the subsequent 5-9 years.139 cases of leprosy were identified by May, 1995; 93 of these were diagnostically certain, definitely postvaccination cases. Among scar-positive individuals, a second BCG vaccination gave further protection against leprosy (about 50%) over a first BCG vaccination. The rate ratio for all diagnostically certain, definitely postvaccination cases, all ages, was 0.51 (95% CI 0.25-1.03

1996 Lancet Controlled trial quality: predicted high

658. Tuberculosis screening among homeless persons with AIDS living in single-room-occupancy hotels

Tuberculosis screening among homeless persons with AIDS living in single-room-occupancy hotels Tuberculosis screening among homeless persons with AIDS living in single-room-occupancy hotels Tuberculosis screening among homeless persons with AIDS living in single-room-occupancy hotels Layton M, Cantwell M, Dorsinville G, Valway S, Onorato M, Frieden T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Tuberculosis screening strategies. In particular: 1)interviewing for symptoms and tuberculosis history; 2) skin tests using the Mantoux method, and conducting anergy tests; 3) portable frontal-view radiographs. Type of intervention Screening and diagnosis. Economic study type Cost-effectiveness analysis. Study population

1995 NHS Economic Evaluation Database.

659. Isoniazid prophylactic therapy for tuberculosis in HIV-seropositive patients: a least-cost analysis

Isoniazid prophylactic therapy for tuberculosis in HIV-seropositive patients: a least-cost analysis Isoniazid prophylactic therapy for tuberculosis in HIV-seropositive patients: a least-cost analysis Isoniazid prophylactic therapy for tuberculosis in HIV-seropositive patients: a least-cost analysis Masobe P, Lee T, Price M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Tuberculosis isoniazid chemoprophylactic (TIP) therapy in HIV-positive people. Type of intervention Treatment; primary prevention. Economic study type Cost-effectiveness analysis Study population HIV-infected adults. Setting Hospital setting. The economic study was carried out at the University of Witwatersrand, Johannesburg, South Africa. Dates to which data

1995 NHS Economic Evaluation Database.

660. The efficacy of Bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature

The efficacy of Bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature The efficacy of Bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature The efficacy of Bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature Colditz G A, Berkey C S, Mosteller F (...) , Brewer T F, Wilson M E, Burdick E, Fineberg H V Authors' objectives To quantify the efficacy of vaccination of infants with bacillus Calmette-Guerin (BCG) against tuberculosis. Searching MEDLINE was searched (search years unclear) using the index terms 'BCG vaccine', 'tuberculosis' and 'human', and the references of all retrieved articles were reviewed. Unpublished studies were identified by examining previously compiled lists of BCG studies and articles providing an overview of these studies

1995 DARE.